BOMBAY COURT STAYS GLAXO PLANT SUSPENSION ORDER
The Bombay High Court has stayed until December 10 the Maharashtra Minister of Health, Pushpa Hiray's order suspending Glaxo's license to manufacture drugs at its Worli factory for ten days effective from November 18. The closure was reportedly ordered following reports that the company had allegedly allowed rejected drugs to be sold in the market through scrap dealers rather than destroying them.
Glaxo India has filed a suit in the Bombay High Court challenging the Health Minister's decision to uphold the Food and Drug Administration order directing it to close down for ten days.
The closure order was passed on June 14 this year by the FDA's joint commissioner after rejected drugs from the Worli factory were found to have been siphoned out of its premises instead of being destroyed as required under Good Manufacturing Practice, by which the company is bound.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze